Related Experiment Video
Updated: Aug 24, 2025
Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
Thermodynamic and structural characterization of an optimized peptide-based inhibitor of the influenza polymerase
Kateřina Radilová1, Václav Zima2, Michal Kráľ1
1Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo n. 2, 16610, Prague 6, Czech Republic; First Faculty of Medicine, Charles University, Kateřinská 1660/32, 12108, Prague, 2, Czech Republic.
Abstract:
Influenza virus causes severe respiratory infection in humans. Current antivirotics target three key proteins in the viral life cycle: neuraminidase, the M2 channel and the endonuclease domain of RNA-dependent-RNA polymerase. Due to the development of novel pandemic strains, additional antiviral drugs targetting different viral proteins are still needed. The protein-protein interaction between polymerase subunits PA and PB1 is one such possible target. We recently identified a modified decapeptide derived from the N-terminus of the PB1 subunit with high affinity for the C-terminal part of the PA subunit. Here, we optimized its amino acid hotspots to maintain the inhibitory potency and greatly increase peptide solubility. This allowed thermodynamic characterization of peptide binding to PA. Solving the X-ray structure of the peptide-PA complex provided structural insights into the interaction. Additionally, we optimized intracellular delivery of the peptide using a bicyclic strategy that led to improved inhibition in cell-based assays.
Insights
Researchers optimized a peptide targeting influenza virus polymerase, enhancing its solubility and delivery for improved antiviral activity against new strains.
Area of Science:
- Virology
- Structural Biology
- Drug Discovery
Background:
- Influenza virus poses a significant threat, necessitating new antiviral strategies beyond current neuraminidase, M2 channel, and RNA-dependent-RNA polymerase inhibitors.
- The interaction between influenza polymerase subunits PA and PB1 presents a potential target for novel antiviral drug development.
- Existing antivirals face challenges due to the emergence of novel pandemic influenza strains.
Purpose of the Study:
- To optimize a decapeptide inhibitor targeting the PA-PB1 protein-protein interaction in the influenza virus polymerase.
- To enhance peptide solubility and enable thermodynamic and structural characterization of its binding to the PA subunit.
- To improve intracellular delivery of the peptide for enhanced efficacy in cell-based influenza inhibition assays.
Main Methods:
- Amino acid optimization of a decapeptide derived from the PB1 subunit to enhance solubility while maintaining inhibitory potency against the PA subunit.
- Thermodynamic characterization of the optimized peptide's binding to the PA subunit.
- X-ray crystallography to determine the structural basis of the peptide-PA complex interaction.
- Development of a bicyclic strategy for optimized intracellular delivery of the peptide.
Main Results:
- Optimized peptide demonstrated maintained inhibitory potency against influenza PA subunit with significantly increased solubility.
- Thermodynamic analysis provided insights into the binding kinetics and affinity of the peptide to PA.
- The X-ray structure revealed the molecular interactions between the peptide and the PA subunit.
- The bicyclic delivery strategy led to improved intracellular peptide levels and enhanced inhibition of influenza virus in cell-based assays.
Conclusions:
- The optimized peptide represents a promising lead compound for developing new influenza antivirals targeting the PA-PB1 interaction.
- Structural and thermodynamic data provide a foundation for further rational drug design and optimization.
- Enhanced intracellular delivery strategies are crucial for the therapeutic efficacy of peptide-based antivirals.
- Targeting protein-protein interactions within the influenza polymerase complex offers a viable strategy against emerging viral strains.
